Nanoparticle-enabled hydrogel-based microneedles for alopecia therapy: From microenvironment rescue to follicular...

Despite advances in alopecia therapy, efficient follicular drug delivery and coordinated remodeling of the diseased follicular microenvironment remain challenging. Nanoparticle-enabled hydrogel-based microneedles (NP-HMNs) integrate skin-barrier penetration, localized hydrogel-mediated delivery, and nanocarrier-enabled drug protection and functional modulation, offering a promising platform for pathology-guided hair regeneration. Herein, we review recent advances in NP-HMNs and organize alopecia-associated abnormalities into six interrelated pathological barriers: signaling dysregulation, hormonal imbalance, immune dysfunction, oxidative stress, vascular impairment, and nutritional or metabolic disturbances. We discuss how microneedle-mediated micro-injury, hydrogel matrices, nanocarriers, and therapeutic cargos can be rationally matched to these barriers, and summarize representative therapeutic applications across different alopecia subtypes. Finally, we address major translational challenges involving dose reproducibility, long-term safety, disease-relevant preclinical models, scalable manufacturing, quality control, and regulatory classification, and discuss future directions toward clinically translatable NP-HMN systems. STATEMENT OF SIGNIFICANCE: Alopecia is governed by interconnected pathological barriers that disrupt the follicular microenvironment and constrain regeneration. This Review establishes a pathology-guided framework linking six major pathological barriers to the rational design of nanoparticle-hydrogel microneedles (NP-HMNs), while dissecting the therapeutic roles and synergistic mechanisms of microneedles, hydrogels, nanoparticles, and incorporated cargos. Beyond material-centered classification, we emphasize how pathological features guide component selection, spatial organization, release behavior, and therapeutic function. Importantly, we critically examine major translational barriers, including preclinical model heterogeneity, dose and pharmacokinetic uncertainty, repeated-use biosafety, regulatory classification, sterilization, manufacturing scale-up, and quality control. This framework bridges alopecia pathobiology, mechanistic biomaterial design, and clinically translatable NP-HMN development.